All In Biotech

Drug Trial Radar · NCT07474649

A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events

Effects of Bempedoic Acid/Ezetimibe/High-intensity Statin on Plaque Regression and Stabilisation of Coronary Atherosclerosis Among Patients Without Cardiovascular Events

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

103

Planned (sponsor's estimate)

Start

Sep 14, 2026

Primary completion

Jun 1, 2028

Study completion Oct 2, 2028

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Mar 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorvastatin or rosuvastatin on changes in coronary plaque burden and plaque morphology in patients with coronary atherosclerosis without significant obstructive coronary artery disease and without prior history of an ischemic vascular event.

Conditions

  • Coronary Atherosclerosis
  • Mixed Dyslipidemia
  • Hypercholesterolemia

Interventions

  • Bempedoic acidDrug

    FDC: 180 mg

  • EzetimibeDrug

    FDC: 10 mg

  • RosuvastatinDrug

    20 mg dose

  • AtorvastatinDrug

    40 mg dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualised change in percentage plaque burden (Δ%PB)Time frame: Baseline up to 12 months

Locations

12 sites in 3 countries. Site status is shown where the registry gives one.

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany · Not yet recruiting

  • UKE Hamburg

    Hamburg, Germany · Not yet recruiting

  • Universität Mainz

    Mainz, Germany · Recruiting

  • Heidelberg University

    Mannheim, Germany · Not yet recruiting

  • IRCCS Policlinico San Donato

    Milan, Italy · Not yet recruiting

  • Cardiology, IRCCS San Raffaele Scientific Institute

    Milan, Italy · Not yet recruiting

  • AOU Federico II di Napoli

    Naples, Italy · Not yet recruiting

  • IRCCS Ospedale Sacro Cuore - Don Calabria

    Negrar, Italy · Not yet recruiting

  • Hospital Quironsalud Barcelona

    Barcelona, Spain · Not yet recruiting

  • Hospital San Rafael

    Madrid, Spain · Not yet recruiting

  • CUN (Clínica Universitaria de Navarra)

    Madrid, Spain · Not yet recruiting

  • Hospital Universitario Quironsalud Madrid

    Madrid, Spain · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.